News Headline Summary

Bristol Myers (BMY) says US patent on Hepatitis B drug Baraclude invalidated by Delaware federal court

- Co. loses patent challenge from generic drug maker Teva.

Reaction details (14:38)

- In immediate reaction, Co. shares are unmoved, trades at USD 36.83.

12 Feb 2013 - 14:33 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: